Lindbäck S, Vizzard J, Cooper D A, Gaines H
Department of Infectious Diseases, Karolinska Institute, Huddinge Hospital, S-141 86 Huddinge, Sweden.
J Infect Dis. 1999 Jun;179(6):1549-52. doi: 10.1086/314777.
Eighty-five subjects with symptomatic primary (P) human immunodeficiency virus (HIV) type 1 infection were analyzed in a retrospective cohort study to investigate the long-term clinical benefit of antiretroviral treatment during PHIV infection. Zidovudine treatment was initiated (PHIV treatment group) in 21 persons a median of 9 days after onset of PHIV symptoms and continued for a median of 55 days (range, 21-99). Sixty-four subjects did not receive early antiretroviral treatment (PHIV nontreatment group). After follow-up for 3-10 years, 33 subjects had developed AIDS and 22 subjects had died of AIDS. The median times for progression to AIDS and death were 6.4 and 9.1 years, respectively. Progression rates did not differ between the PHIV treatment and nontreatment groups. Zidovudine treatment initiated during PHIV infection did not improve long-term outcome after symptomatic PHIV infection.
在一项回顾性队列研究中，对85例有症状的原发性1型人类免疫缺陷病毒（HIV）感染患者进行了分析，以研究抗逆转录病毒治疗在原发性HIV感染期间的长期临床益处。21例患者在原发性HIV症状出现后中位9天开始齐多夫定治疗（原发性HIV治疗组），并持续了中位55天（范围为21 - 99天）。64例患者未接受早期抗逆转录病毒治疗（原发性HIV未治疗组）。经过3 - 10年的随访，33例患者发展为艾滋病，22例患者死于艾滋病。进展为艾滋病和死亡的中位时间分别为6.4年和9.1年。原发性HIV治疗组和未治疗组之间的进展率没有差异。在原发性HIV感染期间开始的齐多夫定治疗并不能改善有症状的原发性HIV感染后的长期结局。
